Recent

% | $
Quotes you view appear here for quick access.

IMMUNICON CORP Message Board

  • ohioflake ohioflake Jan 10, 2007 12:22 PM Flag

    ghdx....

    is up big, maybe helping IMMC.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • GHDX is my other big biotech holding and there is some marginal relationship, though the technology is totally different. GHDX has developed a test based on 21 genes (out of thousands) that will predict the potential for breast cancer to re-occur. This can help determine whether a patient should receive chemo in addition to surgery and radiation. The test is done on a tumor sample. So, they help determine treatment at time of diagnosis, and IMMC monitors that treatment to assure that it is working. They are really complimentary.

      • 1 Reply to flazney
      • Excellent point regarding the complementary nature of GHDX and IMMC's products. IMMC's CellSearch should indeed also be used to "check-up" on a patient's GenomicHealth OncoTypeDX test results. CellSearch's test result can ensure sure that a breast, colorectal, or prostate patient's CTCs are indeed staying under 5 CTCs total.
        ----------------------------------------

        Makes me wonder if there is room for a collaborative study or deal between Genomic Health and Immunicon for their tests to help insurers keep costs under control.
        ------------------------------------------

        Flazney rightly points out that GHDX's "test is done on a tumor sample. So, they help determine treatment at time of diagnosis, and IMMC monitors that treatment to assure that it is working. They are really complimentary."

        -------------------------------------------------------
        Shares of Genomic Health (GHDX - commentary - Cramer's Take - Rating) jumped 15% after the company said insurer UnitedHealth (UNH - commentary - Cramer's Take - Rating) will cover the use its Oncotype DX tests to detect the risk of recurrence in breast cancer patients.

        The tests are used to measure the likelihood of breast cancer recurrence in patients who've already been diagnosed, and to predict the possible benefit a patient might have from chemotherapy, Genomic Health said.

        The stock was gaining $3.19 to $23.87.

 
IMMCQ
0.0060.000(0.00%)Jul 24 3:27 PMEDT